CIK 0001604464 · Non-accelerated filer<br>Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460920988
- Phone
- 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $40,883
- in 1 filing
Net +$959,111. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-09 | Ciechanover Isaac E. Chief Executive Officer | Shares withheld for taxes | −20,324 | $38.49 | $782K | 334,618 |
| 2019-02-06 | Ciechanover Isaac E. Chief Executive Officer | Shares withheld for taxes | −24,683 | $38.47 | $950K | 375,611 |
| 2019-02-06 | Koppikar Utpal Chief Financial Officer | Grant or award | +17,063 | 64,063 | ||
| 2019-02-06 | Koppikar Utpal Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +34,125 | 34,125 | ||
| 2019-02-06 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −2,677 | $38.04 | $102K | 282,903 |
| 2019-02-06 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −9,698 | $38.78 | $376K | 273,205 |
| 2019-02-06 | Haqq Christopher EVP, R&D & Chief Scientific Of | Shares withheld for taxes | −1,512 | $38.47 | $58K | 271,693 |
| 2019-02-06 | Haqq Christopher EVP, R&D & Chief Scientific Of | Grant or award | +15,000 | 286,693 | ||
| 2019-02-06 | Haqq Christopher EVP, R&D & Chief Scientific Of | Grant or award · Employee Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2019-02-06 | Ciechanover Isaac E. Chief Executive Officer | Shares withheld for taxes | −24,683 | 375,611 | ||
| 2019-02-06 | Berger Dietmar Global Head of R&D | Grant or award | +25,000 | 75,000 | ||
| 2019-02-06 | Berger Dietmar Global Head of R&D | Grant or award · Employee Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2019-02-06 | Kim Mina Senior VP & General Counsel | Grant or award | +17,063 | 60,063 | ||
| 2019-02-06 | Kim Mina Senior VP & General Counsel | Grant or award · Employee Stock Option (Right to Buy) | +34,125 | 34,125 | ||
| 2019-02-06 | Porter Derrell SVP, Head of Global Commercial | Shares withheld for taxes | −1,216 | $38.47 | $47K | 11,284 |
| 2019-02-06 | Porter Derrell SVP, Head of Global Commercial | Grant or award | −12,313 | 23,597 | ||
| 2019-02-06 | Porter Derrell SVP, Head of Global Commercial | Grant or award · Employee Stock Option (Right to Buy) | +24,625 | 24,625 | ||
| 2019-02-06 | Newell Joe Chief Tech. Operations Officer | Shares withheld for taxes | −2,212 | $38.47 | $85K | 29,646 |
| 2019-02-06 | Newell Joe Chief Tech. Operations Officer | Grant or award | −17,500 | 47,146 | ||
| 2019-02-06 | Newell Joe Chief Tech. Operations Officer | Grant or award · Employee Stock Option (Right to Buy) | +35,000 | 35,000 |
Page 23 of 29 · 569 trades